Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report

BG Feagan; M Lemann; R Befrits; W Connell; G D'Haens; S Ghosh; P Michetti; T Ochsenkuhn; R Panaccione; S Schreiber; M Silverberg; D Sorrentino; C.J. van der Woude; S Vermeire; P Rutgeerts

doi:10.1002/ibd.21870

Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report

BG Feagan, M Lemann, R Befrits, W Connell, G D'Haens, S Ghosh, P Michetti, T Ochsenkuhn, R Panaccione, S Schreiber, M Silverberg, D Sorrentino, C.J. van der Woude, S Vermeire, P Rutgeerts

Gastroenterology & Hepatology

Research output: Contribution to journal › Article › Academic › peer-review

61 Citations (Scopus)

Abstract

Background: Symptom relief is the traditional treatment goal in Crohn's disease (CD). New goals including mucosal healing and bowel preservation are now achievable with tumor necrosis factor (TNF) antagonists. Infliximab and adalimumab are approved as second-line treatments for severe, active CD. Certolizumab pegol is approved only in the U.S. and Switzerland as second-line treatment for moderate-to-severe, active CD. Data from trials of infliximab suggest that high-risk patients and patients with active inflammation (CRP elevation and/or ileocolonic ulcers) may benefit from earlier use of this drug.

Original language	Undefined/Unknown
Pages (from-to)	152-160
Number of pages	9
Journal	Inflammatory Bowel Diseases
Volume	18
Issue number	1
DOIs	https://doi.org/10.1002/ibd.21870
Publication status	Published - 2012

Access to Document

10.1002/ibd.21870

http://hdl.handle.net/1765/37183

Cite this

Feagan, BG., Lemann, M., Befrits, R., Connell, W., D'Haens, G., Ghosh, S., Michetti, P., Ochsenkuhn, T., Panaccione, R., Schreiber, S., Silverberg, M., Sorrentino, D., van der Woude, C. J., Vermeire, S., & Rutgeerts, P. (2012). Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report. Inflammatory Bowel Diseases, 18(1), 152-160. https://doi.org/10.1002/ibd.21870

@article{669620faeb974ec996f3090672c96a25,

title = "Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report",

abstract = "Background: Symptom relief is the traditional treatment goal in Crohn's disease (CD). New goals including mucosal healing and bowel preservation are now achievable with tumor necrosis factor (TNF) antagonists. Infliximab and adalimumab are approved as second-line treatments for severe, active CD. Certolizumab pegol is approved only in the U.S. and Switzerland as second-line treatment for moderate-to-severe, active CD. Data from trials of infliximab suggest that high-risk patients and patients with active inflammation (CRP elevation and/or ileocolonic ulcers) may benefit from earlier use of this drug.",

author = "BG Feagan and M Lemann and R Befrits and W Connell and G D'Haens and S Ghosh and P Michetti and T Ochsenkuhn and R Panaccione and S Schreiber and M Silverberg and D Sorrentino and {van der Woude}, C.J. and S Vermeire and P Rutgeerts",

year = "2012",

doi = "10.1002/ibd.21870",

language = "Undefined/Unknown",

volume = "18",

pages = "152--160",

journal = "Inflammatory Bowel Diseases",

issn = "1078-0998",

publisher = "Oxford University Press",

number = "1",

}

Feagan, BG, Lemann, M, Befrits, R, Connell, W, D'Haens, G, Ghosh, S, Michetti, P, Ochsenkuhn, T, Panaccione, R, Schreiber, S, Silverberg, M, Sorrentino, D, van der Woude, CJ, Vermeire, S & Rutgeerts, P 2012, 'Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report', Inflammatory Bowel Diseases, vol. 18, no. 1, pp. 152-160. https://doi.org/10.1002/ibd.21870

TY - JOUR

T1 - Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report

AU - Feagan, BG

AU - Lemann, M

AU - Befrits, R

AU - Connell, W

AU - D'Haens, G

AU - Ghosh, S

AU - Michetti, P

AU - Ochsenkuhn, T

AU - Panaccione, R

AU - Schreiber, S

AU - Silverberg, M

AU - Sorrentino, D

AU - van der Woude, C.J.

AU - Vermeire, S

AU - Rutgeerts, P

PY - 2012

Y1 - 2012

N2 - Background: Symptom relief is the traditional treatment goal in Crohn's disease (CD). New goals including mucosal healing and bowel preservation are now achievable with tumor necrosis factor (TNF) antagonists. Infliximab and adalimumab are approved as second-line treatments for severe, active CD. Certolizumab pegol is approved only in the U.S. and Switzerland as second-line treatment for moderate-to-severe, active CD. Data from trials of infliximab suggest that high-risk patients and patients with active inflammation (CRP elevation and/or ileocolonic ulcers) may benefit from earlier use of this drug.

AB - Background: Symptom relief is the traditional treatment goal in Crohn's disease (CD). New goals including mucosal healing and bowel preservation are now achievable with tumor necrosis factor (TNF) antagonists. Infliximab and adalimumab are approved as second-line treatments for severe, active CD. Certolizumab pegol is approved only in the U.S. and Switzerland as second-line treatment for moderate-to-severe, active CD. Data from trials of infliximab suggest that high-risk patients and patients with active inflammation (CRP elevation and/or ileocolonic ulcers) may benefit from earlier use of this drug.

U2 - 10.1002/ibd.21870

DO - 10.1002/ibd.21870

M3 - Article

SN - 1078-0998

VL - 18

SP - 152

EP - 160

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

IS - 1

ER -